Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Pipeline & R&D

CG Oncology eyes two FDA filings after bladder cancer trial success

The US biotech says its oncolytic virus cretostimogene worked in a Phase 3 study of lower-risk disease, while it enlarges one planned regulatory submission and schedules another.

16 Nov 2026 · CG Oncology, Inc. CGON · Company news

CG Oncology is lining up two separate US regulatory submissions for cretostimogene grenadenorepvec, its intravesical therapy for bladder cancer, after announcing on 16 November 2026 that the Phase 3 PIVOT-006 study achieved its main goal. The company has not published any commercial projections, and none are assumed here.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): CG Oncology, Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More Pipeline & R&DAll →